ASND
Ascendis Pharma AS
227.90$
+0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.5% | -2.8% | -5.5% | +44.2% | +7.8% | -10.0% | +2.5% | +6.1% | +12.8% | +54.0% | +13.9% | |
| – | -4.1% | -5.5% | -5.5% | +55.2% | +8.9% | -13.1% | +3.4% | +6.8% | +8.9% | +1.4% | +23.7% | |
| – | -11.1% | -18.3% | -19.2% | +141.8% | -10.5% | -7.4% | -4.6% | +9.1% | +14.2% | -6.9% | +41.6% | |
| – | -12.3% | -19.8% | -19.2% | +141.8% | -10.5% | -7.4% | -4.6% | +9.1% | +14.2% | -6.9% | +41.6% | |
| – | +33.9% | +14.5% | +19.6% | -32.7% | +402.4% | -59.9% | +65.6% | +33.3% | +7.0% | +24.9% | +13.8% | |
| – | +10.5% | +11.4% | +8.0% | +5.7% | +11.4% | -0.9% | +3.5% | -0.4% | -0.2% | +4.4% | -1.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +5.7% | – | |
| – | -79.4% | +365.5% | -2.7% | -1.9% | -87.0% | +633.4% | -3.0% | -1.3% | -94.3% | – | – | |
| – | +2.6% | +7.1% | +3.7% | +10.3% | +7.9% | -2.6% | +1.9% | +4.2% | +10.2% | +3.6% | -44.0% | |
| – | +246.2% | +8.5% | +6.1% | -1.1% | +8.3% | -2.5% | +5.6% | +5.5% | +8.4% | +5.5% | -58.8% | |
| – | +1,558.4% | +0.9% | +3.2% | -0.8% | +9.3% | -0.3% | -5.6% | +4.3% | +0.8% | +5.1% | -87.2% | |
| – | -22.2% | 0.0% | +5.3% | -24.4% | +28.1% | -12.5% | +11.1% | -16.1% | +15.3% | -13.2% | +32.0% | |
| – | -2.8% | -57.0% | -4.6% | +54.7% | +7.7% | -2.1% | -7.6% | +0.4% | +16.3% | +0.2% | -0.4% | |
| – | – | – | – | – | – | – | – | – | – | – | +194.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.6% | +0.5% | +0.8% | +2.1% | +2.1% | +0.4% | +6.5% | -4.6% | +0.6% | +5.1% | +5.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.